NICE says cash back scheme 'not standard'

The NHS 'cash back' scheme for bortexomib (Velcade) approved by NICE last week, is unlikely to become the norm, say experts.

For the first time, NICE approved NHS use of a drug under a response–rebate scheme.

This means that if a patient shows no response to the drug, the manufacturer has to refund its cost to the NHS.

But NICE said the scheme was only considered after being suggested by manufacturer Janssen-Cilag.

If response–rebate is to be considered in the future it would have to be suggested by manufacturers and be approved in principle by the DoH.

A NICE spokesman said: ‘There are a number of factors that might need to be considered, such as whether it would be clinically appropriate for continuation of treatment to be determined on the basis of an appropriate response measure and how well the response measure predicts actual health outcomes.’

rachel.liddle@haymarket.com

More information about bortexomib on the NICE website.

Comment below and tell us what you think

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register

Already registered?

Sign in

Follow Us:

Just published

BMA mourns 'dark death toll' as UK passes 100,000 COVID-19 deaths

BMA mourns 'dark death toll' as UK passes 100,000 COVID-19 deaths

More than 100,000 people have now died from COVID-19 in the UK, five times the death...

UK COVID-19 vaccination programme tracker

UK COVID-19 vaccination programme tracker

GPs across the UK are playing a leading role in the largest-ever NHS vaccination...

Viewpoint: End-of-life care in care homes goes well beyond COVID-19

Viewpoint: End-of-life care in care homes goes well beyond COVID-19

Best practice standards for GPs and teams caring for older people in care homes -...

Locum GPs left behind in patchy COVID-19 vaccine rollout

Locum GPs left behind in patchy COVID-19 vaccine rollout

COVID-19 vaccination for locum GPs has trailed behind the rollout to other doctors,...

Four in five over-80s have had first COVID-19 jab despite weekend slump in vaccinations

Four in five over-80s have had first COVID-19 jab despite weekend slump in vaccinations

Almost 80% of people aged over 80 in the UK have have had at least one dose of COVID-19...

Fitness to practise and revalidation to continue despite pandemic, GMC confirms

Fitness to practise and revalidation to continue despite pandemic, GMC confirms

Revalidation and ongoing fitness to practise cases will continue despite huge pressure...